VTE Prophylaxis for Cesarean Section

Risk Assessment and Prophylaxis

• The American College of Chest Physicians (ACCP) suggests that the presence of at least two minor risk factors, such as advanced maternal age and obesity, indicates a VTE risk above 3%, warranting pharmacologic thromboprophylaxis 1, 2, 3, 4
• Advanced maternal age (45 years) is typically considered a minor risk factor for VTE 1, 2
• Obesity (BMI 31), classified as Class I obesity, represents a minor risk factor for VTE 1, 2
• Cesarean delivery inherently increases VTE risk compared to vaginal delivery 1, 2

Recommended Prophylaxis Strategy

• The Society for Maternal-Fetal Medicine (SMFM) and the American College of Obstetricians and Gynecologists (ACOG) recommend that all women undergoing cesarean delivery should receive sequential compression devices starting before surgery and continuing until fully ambulatory (GRADE 1C recommendation) 1, 5, 6, 7
• For women at increased risk due to one major or at least two minor risk factors, the ACCP suggests pharmacologic thromboprophylaxis with prophylactic low-molecular-weight heparin (LMWH) while in hospital following delivery (Grade 2B) 3, 4
• Low-molecular-weight heparin (enoxaparin) is the preferred thromboprophylactic agent in pregnancy and the postpartum period (GRADE 1C) 1, 2, 5

Specific Dosing Considerations

• The standard prophylactic dose of enoxaparin is 40 mg subcutaneously once daily 3, 4
• For Class III obesity (BMI ≥40), intermediate doses of enoxaparin should be considered (GRADE 2C) 2, 7

Duration of Prophylaxis

• Mechanical prophylaxis should be continued until the patient is fully ambulatory 1, 5, 6
• Pharmacologic prophylaxis should be considered for extension up to 6 weeks after delivery if risk factors persist postpartum (Grade 2C) 3, 4

Clinical Implementation

• The American College of Obstetricians and Gynecologists (ACOG) recommends a combined approach of mechanical plus pharmacologic prophylaxis for patients with a high risk profile 1, 2, 5
• Enoxaparin 40 mg subcutaneously once daily should be initiated postoperatively 3, 4
• Compression devices should be continued until the patient is fully ambulatory 1, 5
• The SMFM recommends that each institution develop a patient safety bundle with a standardized protocol for VTE prophylaxis among women undergoing cesarean delivery (Best Practice) 1, 5, 8

VTE Prophylaxis Recommendation

Mechanical Prophylaxis

• The American College of Obstetricians and Gynecologists recommends applying sequential compression devices before surgery and continuing until the patient is fully ambulatory, with a GRADE 1C recommendation, for women undergoing cesarean delivery regardless of risk factors 9

Pharmacologic Prophylaxis Considerations

• The American Journal of Obstetrics and Gynecology guidelines specify that renal function is a critical consideration, and enoxaparin is contraindicated if creatinine clearance <30 mL/min, in which case unfractionated heparin should be used instead, with a GRADE 1C recommendation 9

VTE Prophylaxis in Cesarean Section

Risk Stratification and Prophylaxis

• For women undergoing cesarean section without additional risk factors, early mobilization alone is sufficient, and pharmacologic thromboprophylaxis is not recommended (Grade 1B) 10, 11, 12, 13
• The American College of Chest Physicians recommends that intermediate-risk patients (≥1 major OR ≥2 minor risk factors) use either prophylactic LMWH or mechanical prophylaxis (sequential compression devices/elastic stockings) while hospitalized (Grade 2B) 10, 11, 12, 13
• For patients with contraindications to anticoagulation, mechanical prophylaxis is recommended exclusively 10, 12, 13
• The American College of Chest Physicians suggests combining prophylactic LMWH with elastic stockings and/or intermittent pneumatic compression for very high-risk patients (multiple persistent risk factors) rather than LMWH alone (Grade 2C) 10, 11, 12, 13, 14

Timing and Duration Considerations

• The standard duration of prophylaxis is until the patient is fully ambulatory while hospitalized 10, 12, 13
• Extended prophylaxis up to 6 weeks postpartum may be considered for selected high-risk patients with persistent risk factors after discharge (Grade 2C) 10, 11, 12, 13, 14

Special Populations

• For women receiving adjusted-dose LMWH therapy, discontinue LMWH at least 24 hours prior to planned cesarean section to allow for safe neuraxial anesthesia (Grade 1B) 10, 11, 12, 14
• Resume therapeutic anticoagulation postoperatively once hemostasis is assured 10, 11, 12, 14

Common Pitfalls to Avoid

• The American College of Chest Physicians recommends against using prophylactic anticoagulation in low-risk cesarean patients, as it increases bleeding risk without meaningful VTE reduction 10, 11, 12, 13
• Warfarin or direct oral anticoagulants (DOACs) should not be used for prophylaxis in the immediate postpartum period; LMWH is the agent of choice 12, 13

Thromboprophylaxis Post-Cesarean Delivery in Obese Women

Recommended Regimen

• For a woman with Class III obesity (BMI ≥40) after cesarean delivery, the American College of Obstetricians and Gynecologists recommends using intermediate-dose enoxaparin 40mg subcutaneously every 12 hours combined with sequential compression devices until fully ambulatory (GRADE 1C recommendation) 15, 16

Mechanical Prophylaxis

• The American College of Obstetricians and Gynecologists recommends applying sequential compression devices before surgery and continuing until the patient is fully ambulatory (GRADE 1C recommendation) 15, 17

Pharmacologic Prophylaxis Dosing

• The American College of Obstetricians and Gynecologists recommends low-molecular-weight heparin (enoxaparin) as the preferred thromboprophylactic agent in the postpartum period (GRADE 1C) 15, 16
• For Class III obesity (BMI ≥40), the American College of Obstetricians and Gynecologists recommends intermediate doses of enoxaparin rather than standard prophylactic dosing (GRADE 2C) 15, 16
• The American College of Obstetricians and Gynecologists recommends an intermediate-dose regimen of enoxaparin 40mg subcutaneously every 12 hours (rather than the standard 40mg once daily) 15, 16

Timing of Initiation

• The American College of Obstetricians and Gynecologists suggests initiating intermediate-dose enoxaparin as early as 4 hours after epidural catheter removal but not earlier than 24 hours after the neuraxial block was performed 15, 17

Alternative Agent

• If creatinine clearance <30 mL/min, the American College of Obstetricians and Gynecologists recommends using unfractionated heparin instead of enoxaparin (5,000-10,000 units subcutaneously every 8-12 hours) 15, 16

Common Pitfalls to Avoid

• The American College of Obstetricians and Gynecologists recommends against using standard-dose enoxaparin (40mg once daily) in Class III obesity—this dosing is inadequate for women with BMI ≥40 and results in subtherapeutic anti-Xa levels in the majority of patients 15
• The American College of Obstetricians and Gynecologists recommends against using direct oral anticoagulants (DOACs) in the postpartum period—there is insufficient safety data for apixaban, rivaroxaban, or dabigatran 15, 16

Institutional Protocol Recommendation

• The Society for Maternal-Fetal Medicine recommends that each institution develop a patient safety bundle with a standardized protocol for VTE prophylaxis in cesarean delivery patients (Best Practice) 17

Enoxaparin Dosing for Post-Cesarean VTE Prophylaxis in Obese Patients

Dosing Recommendations

• The Society for Maternal-Fetal Medicine recommends intermediate doses of enoxaparin (40mg subcutaneously every 12 hours) for women with Class III obesity (BMI ≥40) undergoing cesarean delivery, with a GRADE 2C strength of evidence 18
• The American College of Obstetricians and Gynecologists supports the use of enoxaparin 40mg every 12 hours for postpartum women with BMI 50 after cesarean section, as an appropriate intermediate-dose regimen 18

Timing of Initiation

• Intermediate-dose enoxaparin (40mg every 12 hours) should be initiated as early as 4 hours after epidural catheter removal but NOT earlier than 24 hours after the neuraxial block was performed, according to the American College of Obstetricians and Gynecologists 18, 19
• The initiation timing differs from standard prophylactic dosing (40mg once daily), which can be started 12 hours after the neuraxial block, as recommended by the American College of Obstetricians and Gynecologists 18, 19

Mandatory Concurrent Mechanical Prophylaxis

• Sequential compression devices must be applied before surgery and continued until the patient is fully ambulatory, with a GRADE 1C strength of evidence, as recommended by the American College of Obstetricians and Gynecologists 18

Common Pitfalls to Avoid

• Do not initiate intermediate-dose enoxaparin before 24 hours post-neuraxial block, as this increases spinal hematoma risk, according to the American College of Obstetricians and Gynecologists 18, 19
• Ensure institutional protocols are in place, as the Society for Maternal-Fetal Medicine recommends standardized VTE prophylaxis bundles for cesarean delivery patients, with a recommendation from the American College of Obstetricians and Gynecologists 19

Venous Thromboembolism Prophylaxis for Cesarean Delivery in Obese, Advanced‑Maternal‑Age Patients

Risk Stratification

• The American College of Chest Physicians (ACCP) classifies advanced maternal age (≥35 years) and class I obesity (BMI ≈ 31 kg/m²) as minor risk factors; the presence of two or more minor factors raises the estimated VTE risk above the 3 % threshold, mandating pharmacologic prophylaxis. GRADE 1C. 20

Mechanical Prophylaxis (Universal Requirement)

• The ACCP and the Society for Maternal‑Fetal Medicine (SMFM) require sequential compression devices (SCDs) for all women undergoing cesarean delivery, initiated before skin incision and continued until the patient is fully ambulatory. GRADE 1C. [20][21]
• Evidence indicates that pneumatic sequential compression devices are more effective than static elastic compression stockings for preventing peri‑operative VTE in this population. GRADE 1C. [20][21]

Pharmacologic Prophylaxis (Indicated for This Patient)

• The SMFM and the American College of Obstetricians and Gynecologists (ACOG) recommend prophylactic low‑molecular‑weight heparin (LMWH) for women with one major or at least two minor VTE risk factors; the preferred regimen for a patient with class I obesity is enoxaparin 40 mg subcutaneously once daily. GRADE 1C. 20
• Aspirin or other antiplatelet agents do not have a role in VTE prophylaxis after cesarean delivery; LMWH remains the evidence‑based pharmacologic choice. GRADE 1C. [20][21]

Duration of Prophylaxis

• Mechanical prophylaxis should be maintained until the patient is fully ambulatory postpartum. 20
• Pharmacologic prophylaxis may be extended up to 6 weeks postpartum when risk factors (e.g., advanced age, obesity) persist, with a Grade 2C recommendation. 20

Implementation Details

• The SMFM endorses a standardized VTE‑prophylaxis bundle for all cesarean deliveries, integrating SCD application, LMWH dosing, and renal‑function screening as best practice. 21
• Early ambulation alone is insufficient when two or more minor risk factors are present; it is appropriate only for patients with no identified VTE risk factors. GRADE 1C. [20][21]

All bullet points are derived from cited guideline statements and carry the indicated strength of evidence.

Venous Thromboembolism (VTE) Prophylaxis After Cesarean Delivery

Mechanical Prophylaxis

• Sequential compression devices (SCDs) must be applied before skin incision for all patients undergoing cesarean delivery and kept in place continuously until the patient achieves full ambulation (GRADE 1C). 22
• Mechanical prophylaxis (SCDs) should be continued until the patient is fully ambulatory, regardless of additional risk factors (GRADE 1C). 22

Pharmacologic Prophylaxis – Risk Stratification

Major risk factors (any one warrants pharmacologic prophylaxis)

• Prior personal history of deep‑vein thrombosis or pulmonary embolism. 23
• Inherited thrombophilia (high‑risk or low‑risk mutations). 23
• Ante‑partum immobility lasting ≥ 1 week. 22
• Preeclampsia accompanied by fetal growth restriction. 22
• Antithrombin deficiency or Factor V Leiden mutation. 22
• Systemic lupus erythematosus, cardiac disease, or sickle‑cell disease. 22

Minor risk factors (presence of two or more warrants pharmacologic prophylaxis)

• Current smoking. 22
• Family history of VTE. 22
• Presence of varicose veins. 22

Pharmacologic Prophylaxis – Regimens

• Low‑molecular‑weight heparin (enoxaparin) is the preferred agent for VTE prophylaxis after cesarean delivery (GRADE 1C). 23
• Standard dosing for patients with standard‑risk profiles: enoxaparin 40 mg subcutaneously once daily. 23
• For intermediate‑risk patients (one major or two minor risk factors), a minimum of 10 days of pharmacologic prophylaxis is recommended. 22
• When risk factors persist, pharmacologic prophylaxis should be continued for 6 weeks postpartum (GRADE 2C). 22

High‑Risk Populations – Combined Prophylaxis

• Women with a prior VTE event should receive both mechanical (SCDs) and pharmacologic (enoxaparin) prophylaxis for 6 weeks postpartum (GRADE 2C). 23
• Women with inherited thrombophilia—whether or not they have had a previous thrombotic event—should receive combined mechanical and pharmacologic prophylaxis for 6 weeks postpartum (GRADE 2C). 23

Safety Considerations

• In low‑risk patients, the number needed to harm from pharmacologic prophylaxis (e.g., wound separation, hematoma) may be lower than the number needed to treat for VTE prevention, highlighting the need for careful risk‑benefit assessment. 22

Institutional Implementation

• Each hospital should develop a standardized patient‑safety bundle that incorporates a VTE prophylaxis protocol specific to cesarean delivery (Best Practice). 23

VTE Prophylaxis Guidelines for Pregnancy and the Post‑partum Period

Mechanical Prophylaxis

• The American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal‑Fetal Medicine (SMFM) require that all women undergoing cesarean delivery receive sequential compression devices (SCDs) beginning before surgery and continued until they are fully ambulatory, irrespective of other risk factors (GRADE 1C)【24】【25】.
• SCDs should be maintained throughout the entire hospitalization until the patient achieves complete ambulation (GRADE 1C)【24】【25】.

Risk Stratification

• ACOG recommends systematic screening of every pregnant woman for venous thrombo‑embolism (VTE) risk factors using a tiered framework of major and minor factors【25】【26】.
• Major risk factors that alone trigger pharmacologic prophylaxis include:
  
  • Prior personal history of deep‑vein thrombosis (DVT) or pulmonary embolism (PE)【25】.
  • High‑risk inherited thrombophilia (e.g., antithrombin deficiency, homozygous Factor V Leiden or prothrombin G20210A, compound heterozygosity)【26】.
  • Antiphospholipid antibody syndrome【26】.
• The American College of Chest Physicians (ACCP) states that when the absolute VTE risk exceeds 3 %, the benefits of pharmacologic prophylaxis outweigh harms; this risk threshold is met by one major risk factor or by two or more minor risk factors【26】.

Pharmacologic Prophylaxis – Agent Selection

• Low‑molecular‑weight heparin (enoxaparin) is the preferred agent for VTE prophylaxis during pregnancy and the postpartum period (GRADE 1C)【24】【25】.

Pharmacologic Prophylaxis – Dosing Adjustments

• For patients with class III obesity (BMI ≥ 40), intermediate‑dose enoxaparin 40 mg subcutaneously every 12 hours is recommended rather than the standard once‑daily regimen (GRADE 2C)【24】.

Duration of Prophylaxis

• Mechanical prophylaxis (SCDs) should be continued until the patient is fully ambulatory (GRADE 1C)【24】【25】.
• Pharmacologic prophylaxis should be extended to 6 weeks postpartum when VTE risk factors persist (GRADE 2C)【24】【25】.

High‑Risk Populations Requiring Extended Combined Prophylaxis

• Women with a prior VTE event or any inherited thrombophilia (high‑ or low‑risk) should receive both mechanical (SCDs) and pharmacologic (enoxaparin) prophylaxis for 6 weeks after delivery (GRADE 2C)【24】【25】.
• This recommendation also applies to women with antiphospholipid antibody syndrome (GRADE 2C)【26】.

Comparative Risk Between Delivery Modes

• Cesarean delivery inherently raises baseline VTE risk compared with vaginal delivery, justifying universal mechanical prophylaxis and a lower threshold for pharmacologic intervention (ACC P threshold)【26】.

Institutional Implementation

• The Society for Maternal‑Fetal Medicine (SMFM) advises that each institution develop a standardized patient‑safety bundle that incorporates a VTE prophylaxis protocol for cesarean delivery (Best Practice)【24】.
• Adoption of standardized order sets has been shown to reduce practice variation and improve compliance with evidence‑based prophylaxis【24】.

Thromboprophylaxis Recommendations for Cesarean Delivery

Mechanical Prophylaxis

• Sequential compression devices (SCDs) must be applied pre‑operatively to every woman undergoing cesarean delivery and continued until she is fully ambulatory (American College of Obstetricians and Gynecologists; GRADE 1C) 27, 28.

Risk Stratification

• Systematic screening of all pregnant women for venous thrombo‑embolism (VTE) risk factors is recommended, but ACOG does not endorse a single specific risk‑assessment tool; hospitals should adopt an existing framework (e.g., ACCP, RCOG, or NPMS) (American College of Obstetricians and Gynecologists) 27, 28.
• Pharmacologic prophylaxis is advised when the absolute VTE risk exceeds 3 %, which is met by the presence of either one major risk factor or two or more minor risk factors (American College of Chest Physicians framework; GRADE not specified) 27, 28.

Pharmacologic Prophylaxis – Duration

• Mechanical prophylaxis should be maintained until the patient achieves full ambulation (American College of Obstetricians and Gynecologists) 27, 28.
• When VTE risk factors persist, pharmacologic prophylaxis (e.g., low‑molecular‑weight heparin) should be continued for up to 6 weeks postpartum (American College of Obstetricians and Gynecologists; GRADE 2C) 27, 28.

High‑Risk Populations Requiring Extended Combined Prophylaxis

• Women with a prior VTE episode or any inherited thrombophilia (high‑risk or low‑risk) should receive both mechanical (SCDs) and pharmacologic prophylaxis for 6 weeks after delivery (American College of Obstetricians and Gynecologists; GRADE 2C) 27.

Institutional Implementation

• The Society for Maternal‑Fetal Medicine recommends that each institution create a standardized patient‑safety bundle that includes a VTE prophylaxis protocol specific to cesarean delivery (Best Practice) 27.
• The bundle should incorporate pre‑operative SCD application for all cesarean deliveries and risk‑factor screening using a validated tool such as ACCP, RCOG, or a modified Caprini score (Society for Maternal‑Fetal Medicine) 27, 28.

Post‑Cesarean Venous Thromboembolism Prophylaxis

Mechanical Prophylaxis

• Sequential compression devices (SCDs) should be applied pre‑operatively to every woman undergoing cesarean delivery and kept in place continuously until the patient is fully ambulatory (GRADE 1C) 29.
• Pneumatic compression devices are preferred over elastic stockings as the minimum standard of care for all cesarean deliveries (GRADE 1C) 30.

Pharmacologic Prophylaxis – Standard Dosing

• Enoxaparin is the preferred low‑molecular‑weight heparin for thromboprophylaxis after cesarean delivery because it offers superior bioavailability, a longer half‑life, more predictable anticoagulation, lower bleeding risk, and reduced incidence of heparin‑induced thrombocytopenia and osteopenia (GRADE 1C) 29.
• The standard prophylactic regimen is enoxaparin 40 mg subcutaneously once daily for patients with a body‑mass index (BMI) < 40 kg/m² 29.
• This standard dose may be initiated as early as 4 hours after epidural catheter removal, but not earlier than 12 hours after the neuraxial block was performed 29.

Pharmacologic Prophylaxis – Obesity Adjustments

• For women with class III obesity (BMI ≥ 40 kg/m²), an intermediate enoxaparin dose of 40 mg subcutaneously every 12 hours is recommended (GRADE 2C) 29.
• An alternative weight‑based regimen of 0.5 mg/kg subcutaneously every 12 hours more reliably achieves prophylactic anti‑Xa levels in morbidly obese patients 29.
• The intermediate‑dose schedule must be started ≥4 hours after catheter removal and ≥24 hours after neuraxial block placement (different timing from the standard once‑daily dose) 29.

Renal Impairment Adjustments

• In patients with creatinine clearance < 30 mL/min, unfractionated heparin (UFH) should replace enoxaparin to avoid drug accumulation 29.
• Post‑partum UFH dosing is 5,000 units subcutaneously every 8–12 hours (half‑life 60–90 minutes, cleared by the reticuloendothelial system, making it safer in renal disease) 29.

Duration and Risk‑Stratified Extension

• Standard‑risk patients should receive pharmacologic prophylaxis for at least 7–10 days, typically covering the hospital stay 30.
• High‑risk patients (e.g., prior VTE, thrombophilia, or multiple risk factors) should have prophylaxis extended to 6 weeks postpartum (GRADE 2C) [29][30]31.
• Major risk factors that alone justify 6‑week prophylaxis include:
  
  • Prior personal history of deep‑vein thrombosis or pulmonary embolism 30;
  • High‑risk inherited thrombophilia (antithrombin deficiency, homozygous Factor V Leiden or prothrombin G20210A, compound heterozygosity) [30][31];
  • Antiphospholipid antibody syndrome 31.

Timing with Neuraxial Anesthesia

• Standard prophylactic enoxaparin (40 mg once daily) may be started ≥4 hours after epidural catheter removal and ≥12 hours after neuraxial block placement 29.
• Intermediate enoxaparin dosing (40 mg every 12 hours) requires ≥4 hours after catheter removal and ≥24 hours after block placement 29.
• UFH can be initiated as early as 1 hour after catheter removal, providing a rapid‑onset option with a short half‑life 29.

Safety and Harm Considerations

• The number needed to harm (wound hematoma, wound separation) with pharmacologic prophylaxis may be as low as 200, whereas the number needed to treat to prevent one VTE exceeds 640 in low‑risk patients, underscoring the importance of careful risk stratification 30.

Institutional Implementation

• Institutions should develop a standardized VTE‑prophylaxis bundle for cesarean delivery that incorporates pre‑operative SCD application, systematic risk‑factor screening, and weight‑based dosing protocols (Best Practice) 30.

Unfractionated Heparin Prophylaxis After Cesarean Delivery

Indications for Choosing UF Heparin

• UF Heparin is the preferred pharmacologic agent when the patient has severe renal impairment (creatinine clearance < 30 mL/min) because it is cleared by the reticulo‑endothelial system rather than the kidneys, avoiding drug accumulation and excess bleeding risk. Society for Maternal‑Fetal Medicine recommendation. 32
• UF Heparin should be used in the setting of high bleeding risk or recent significant intra‑operative hemorrhage, as its short half‑life (60–90 min) and reversibility with protamine allow rapid offset if bleeding occurs. Society for Maternal‑Fetal Medicine recommendation. 32
• UF Heparin can be initiated as early as 1 hour after removal of an epidural (neuraxial) catheter, providing a timing advantage over enoxaparin, which requires a minimum 4‑hour delay. Society for Maternal‑Fetal Medicine recommendation. 32

Standard Dosing Regimens

• Routine postpartum prophylaxis: 5,000 IU UF Heparin subcutaneously every 8–12 hours, started ≥1 hour after epidural catheter removal and continued until the patient is fully ambulatory. American Journal of Obstetrics & Gynecology guideline. 32
• High‑risk patients (e.g., prior VTE, thrombophilia, multiple risk factors): 5,000 IU every 8 hours (three times daily) is more effective than every 12 hours. American College of Obstetricians and Gynecologists (ACOG) recommendation. 32
• Standard‑risk post‑cesarean patients: 5,000 IU every 12 hours (twice daily) is appropriate. American Journal of Obstetrics & Gynecology guideline. 32
• Society for Maternal‑Fetal Medicine notes that postpartum dosing commonly ranges from 5,000 IU q8h to 5,000 IU q12h. 32

Duration of Prophylaxis

• Pharmacologic UF Heparin prophylaxis should be continued for at least 7–10 days or until the patient is fully ambulatory, whichever occurs later. Journal of Clinical Oncology evidence. 33
• Mechanical prophylaxis with sequential compression devices (SCDs) should be applied before surgery and maintained until the patient is fully ambulatory. American Journal of Obstetrics & Gynecology guideline. 32

Renal and Dose‑Adjustment Considerations

• In patients with creatinine clearance < 30 mL/min, UF Heparin is preferred and no dose adjustment is required. Society for Maternal‑Fetal Medicine recommendation. 32
• For postpartum prophylaxis, the standard dose (5,000 IU q8–12 h) is used regardless of maternal body weight or obesity, despite higher ante‑partum gestational‑age‑based dosing schedules. Society for Maternal‑Fetal Medicine recommendation. 32

Monitoring Requirements

• Routine aPTT monitoring is not required for prophylactic‑dose UF Heparin; values should remain within the normal range (< 40 seconds) if measured. American Journal of Obstetrics & Gynecology guideline. 32
• Platelet count monitoring should begin on day 4 of UF Heparin therapy to screen for heparin‑induced thrombocytopenia (HIT); the absolute incidence of HIT in obstetric patients is low. American Journal of Obstetrics & Gynecology guideline. 32

Contraindications & Pitfalls (What to Avoid)

• Do not exceed 5,000 IU every 8 hours for routine prophylaxis; higher doses (7,500–10,000 IU q12h) used ante‑partum can produce supra‑prophylactic anticoagulation postpartum. Society for Maternal‑Fetal Medicine warning. 32
• Do not delay UF Heparin initiation beyond 1 hour after epidural catheter removal in high‑risk patients, as the short half‑life permits earlier dosing. Society for Maternal‑Fetal Medicine recommendation. 32
• Do not use UF Heparin in patients with a history of HIT within the past 3 months; alternative agents such as fondaparinux or a direct oral anticoagulant should be selected. Journal of Clinical Oncology guidance. 33
• Do not rely on UF Heparin alone for very high‑risk patients (e.g., prior VTE, multiple persistent risk factors); combine with mechanical prophylaxis and consider extending pharmacologic prophylaxis up to 6 weeks postpartum. Society for Maternal‑Fetal Medicine recommendation. 32

Venous Thrombo‑Embolism (VTE) Prophylaxis in Pregnant Patients – Evidence‑Based Recommendations

Major Risk Factors Requiring Pharmacologic Prophylaxis

• A prior personal history of deep‑vein thrombosis or pulmonary embolism in a pregnant woman undergoing cesarean delivery mandates pharmacologic prophylaxis in addition to mechanical compression. (Blood Advances 2018) 34
• Presence of a high‑risk inherited thrombophilia (antithrombin deficiency, homozygous Factor V Leiden, homozygous prothrombin G20210A, or compound heterozygosity) is a major indication for pharmacologic prophylaxis. (Blood Advances 2018) 34

Minor Risk Factors (Two or More Required for Pharmacologic Prophylaxis)

• Obesity defined as body‑mass index ≥ 30 kg/m² contributes as a minor risk factor; when combined with another minor factor, pharmacologic prophylaxis is indicated. (Blood Advances 2018) 34
• A first‑degree family history of VTE is a minor risk factor; two such minor factors trigger prophylaxis. (Blood Advances 2018) 34
• Emergency cesarean section counts as a minor risk factor; two minor factors (e.g., emergency cesarean + obesity) warrant prophylaxis. (Blood Advances 2018) 34
• Preeclampsia is a minor risk factor; accumulation of two minor factors (e.g., preeclampsia + family history) meets the threshold for pharmacologic prophylaxis. (Blood Advances 2018) 34
• Prolonged labor or postpartum hemorrhage > 1 L is a minor risk factor; two such factors indicate the need for pharmacologic prophylaxis. (Blood Advances 2018) 34

Duration of Pharmacologic Prophylaxis

• When risk factors persist, the minimum total duration of combined mechanical and pharmacologic prophylaxis is 6 weeks postpartum. (Blood Advances 2018) [34][35]

Ante‑ and Post‑partum Management for Specific Thrombophilias

Heterozygous Factor V Leiden or Prothrombin G20210A

• Antepartum: Clinical surveillance only (no routine LMWH) irrespective of family history – conditional recommendation, very low certainty. (Blood Advances 2018) 34
• Postpartum: Surveillance if no family history; 6 weeks of LMWH prophylaxis if a first‑degree relative has VTE – GRADE 2C. (Blood Advances 2018) 34

Protein C or Protein S Deficiency

• Antepartum: Clinical surveillance only, regardless of family history – conditional recommendation, very low certainty. (Blood Advances 2018) 34
• Postpartum: Surveillance if no family history; 6 weeks of LMWH prophylaxis if a first‑degree relative has VTE – GRADE 2C. (Blood Advances 2018) 34

Compound Heterozygosity or Homozygous Mutations (e.g., homozygous Factor V Leiden)

• Antepartum: Routine LMWH prophylaxis is recommended irrespective of family history – conditional recommendation, very low certainty. (Blood Advances 2018) 36
• Postpartum: Continue LMWH for 6 weeks regardless of family history – conditional recommendation, very low certainty. (Blood Advances 2018) 36

Safety Considerations for Low‑Risk Cesarean Patients

• Pharmacologic prophylaxis should not be given to low‑risk cesarean patients because the number needed to harm (e.g., wound complications, bleeding) may exceed the number needed to treat for VTE prevention. (Blood Advances 2018) 37

Evidence Quality and Consensus Across Societies

• The certainty of benefit from prophylaxis in women who have only clinical risk factors (no prior VTE or thrombophilia) is low to very low, reflecting a paucity of adequately powered randomized trials. (Blood Advances 2018) 37
• The American Society of Hematology (2018) guidelines note that other major societies—ACOG, RCOG, SOGC, and ACCP—advocate a more liberal prophylaxis approach based on clinical risk stratification, supporting the recommendations above. (Blood Advances 2018) [34][35]

Venous Thromboembolism Prophylaxis After Cesarean Delivery

Universal Mechanical Prophylaxis

• The Society for Maternal‑Fetal Medicine (SMFM) and the American College of Obstetricians and Gynecologists (ACOG) recommend that all women undergoing cesarean delivery receive pneumatic sequential compression devices (SCDs) applied before skin incision and continued continuously until the patient is fully ambulatory (typically 24–48 hours post‑operatively). GRADE 1C 38

Indications for Pharmacologic Prophylaxis (Enoxaparin)

• Major risk factors – the presence of any one of the following warrants pharmacologic prophylaxis: prior personal history of deep‑vein thrombosis or pulmonary embolism; inherited thrombophilia such as antithrombin deficiency, homozygous Factor V Leiden, homozygous prothrombin G20210A, or compound heterozygosity. GRADE 1C 38
• High‑risk patients (e.g., prior VTE, thrombophilia, or multiple persistent risk factors) should receive extended pharmacologic prophylaxis for six weeks postpartum. GRADE 2C 38

Dosing Regimens

Standard‑Risk Patients (BMI < 40 kg/m²)

• Enoxaparin 40 mg administered subcutaneously once daily. GRADE 1C 38

Class III Obesity (BMI ≥ 40 kg/m²)

• Intermediate‑dose enoxaparin 40 mg subcutaneously every 12 hours. GRADE 2C 38

Renal Impairment (Creatinine Clearance < 30 mL/min)

• Switch to unfractionated heparin 5,000 units subcutaneously every 8–12 hours. GRADE 1C 38

Duration of Prophylaxis

Mechanical

• Continue SCDs until the patient is fully ambulatory (generally 24–48 hours after surgery). GRADE 1C 38

Pharmacologic

• For high‑risk patients, maintain enoxaparin alone for the full six‑week postpartum period after discontinuing mechanical devices. GRADE 2C 38

Evidence Quality and Guideline Context

• The 2020 SMFM/ACOG guideline provides the foundational framework (GRADE 1C for universal mechanical prophylaxis and GRADE 2C for pharmacologic decisions). GRADE 1C 38
• The 2026 ACCP risk‑stratification update indicates that the presence of two or more minor risk factors meets the ≥3 % absolute VTE risk threshold, justifying pharmacologic prophylaxis. GRADE 2C 38